Computer model aims to optimize infliximab shots for IBD patients

NCT ID NCT07120152

Not yet recruiting Knowledge-focused Sponsor: Erwin Dreesen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study uses computer simulations to better understand how a subcutaneous (under-the-skin) form of the drug infliximab works in people with inflammatory bowel disease (IBD) and rheumatoid arthritis. Researchers will analyze data from previous trials to create a model that predicts how the drug is absorbed and affects the body. The goal is to help doctors decide which patients should switch to this convenient injection form and when, but no new treatments are being tested directly on participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: subcutaneous infliximab (CT-P13 Remsima®SC)
What this could lead to: If successful, this could help doctors choose the right patients and timing for switching to subcutaneous infliximab, improving treatment convenience and outcomes.
What could go wrong: This is a computer simulation study, not a direct patient trial. The models may not perfectly predict real-world results, and further clinical studies are needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease rheumatoid arthritis ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IBD (INFLAMMATORY BOWEL DISEASE) RA - RHEUMATOID ARTHRITIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.